Dynamic Technology Lab Private Ltd Takes $1.20 Million Position in Penumbra, Inc. (NYSE:PEN)

Dynamic Technology Lab Private Ltd purchased a new stake in shares of Penumbra, Inc. (NYSE:PEN - Free Report) during the fourth quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The firm purchased 4,754 shares of the company's stock, valued at approximately $1,195,000.

Several other large investors have also made changes to their positions in the business. Benjamin F. Edwards & Company Inc. lifted its stake in Penumbra by 171.8% in the 4th quarter. Benjamin F. Edwards & Company Inc. now owns 106 shares of the company's stock worth $27,000 after purchasing an additional 67 shares in the last quarter. RiverPark Advisors LLC bought a new position in Penumbra during the third quarter valued at approximately $42,000. Signaturefd LLC grew its holdings in Penumbra by 27.2% during the 4th quarter. Signaturefd LLC now owns 215 shares of the company's stock valued at $54,000 after buying an additional 46 shares in the last quarter. Covestor Ltd increased its position in Penumbra by 357.9% in the third quarter. Covestor Ltd now owns 348 shares of the company's stock worth $84,000 after purchasing an additional 272 shares during the last quarter. Finally, Picton Mahoney Asset Management bought a new position in Penumbra during the fourth quarter valued at $88,000. 88.88% of the stock is currently owned by hedge funds and other institutional investors.

Insider Buying and Selling at Penumbra

In related news, Director Don W. Kassing sold 778 shares of the firm's stock in a transaction dated Friday, March 1st. The stock was sold at an average price of $234.72, for a total transaction of $182,612.16. Following the sale, the director now owns 1,345 shares of the company's stock, valued at $315,698.40. The sale was disclosed in a filing with the SEC, which is available through the SEC website. In related news, EVP Johanna Roberts sold 600 shares of the business's stock in a transaction on Friday, March 1st. The stock was sold at an average price of $237.68, for a total transaction of $142,608.00. Following the transaction, the executive vice president now directly owns 62,997 shares in the company, valued at approximately $14,973,126.96. The sale was disclosed in a document filed with the SEC, which can be accessed through this link. Also, Director Don W. Kassing sold 778 shares of the stock in a transaction dated Friday, March 1st. The shares were sold at an average price of $234.72, for a total value of $182,612.16. Following the completion of the sale, the director now owns 1,345 shares of the company's stock, valued at $315,698.40. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 10,248 shares of company stock valued at $2,494,349. 5.00% of the stock is currently owned by corporate insiders.

Penumbra Stock Down 0.6 %

Shares of Penumbra stock traded down $1.19 during trading on Tuesday, hitting $200.25. 166,696 shares of the stock traded hands, compared to its average volume of 343,548. The company has a current ratio of 6.12, a quick ratio of 3.51 and a debt-to-equity ratio of 0.02. The stock's fifty day simple moving average is $214.69 and its 200 day simple moving average is $232.56. The firm has a market cap of $7.76 billion, a P/E ratio of 84.49, a price-to-earnings-growth ratio of 2.06 and a beta of 0.57. Penumbra, Inc. has a 52-week low of $180.93 and a 52-week high of $348.67.

Penumbra (NYSE:PEN - Get Free Report) last posted its quarterly earnings results on Tuesday, May 7th. The company reported $0.41 EPS for the quarter, missing the consensus estimate of $0.42 by ($0.01). The business had revenue of $278.70 million during the quarter, compared to the consensus estimate of $274.94 million. Penumbra had a net margin of 8.52% and a return on equity of 7.83%. The company's revenue for the quarter was up 15.5% compared to the same quarter last year. During the same quarter in the prior year, the firm posted $0.23 EPS. On average, equities analysts predict that Penumbra, Inc. will post 2.87 earnings per share for the current fiscal year.

Analysts Set New Price Targets

Several analysts have recently issued reports on the stock. JPMorgan Chase & Co. cut shares of Penumbra from an "overweight" rating to a "neutral" rating and decreased their target price for the company from $284.00 to $250.00 in a research report on Friday, February 23rd. Canaccord Genuity Group lowered their price objective on Penumbra from $284.00 to $272.00 and set a "buy" rating for the company in a research note on Wednesday, May 8th. Needham & Company LLC restated a "hold" rating on shares of Penumbra in a research report on Wednesday, May 8th. Piper Sandler dropped their price objective on shares of Penumbra from $290.00 to $260.00 and set an "overweight" rating for the company in a research note on Wednesday, May 8th. Finally, Truist Financial reduced their target price on shares of Penumbra from $290.00 to $280.00 and set a "buy" rating on the stock in a research note on Friday, March 22nd. Four research analysts have rated the stock with a hold rating and seven have issued a buy rating to the company's stock. According to MarketBeat, Penumbra currently has a consensus rating of "Moderate Buy" and an average price target of $300.64.

Penumbra Company Profile

Penumbra, Inc, together with its subsidiaries, designs, develops, manufactures, and markets medical devices in the United States and internationally. The company offers peripheral products, including the Indigo System for power aspiration of thrombus in the body; Lightning Flash, a mechanical thrombectomy system; Lightning Bolt 7, an arterial thrombectomy system; and CAT RX.